Drug intelligence / Profile preview

ACT Dry Mouth Lozenges

Development stage: Unknown
Lead developer: Chattem
Modality: Small Molecules
Administration: Oral

Overview

ACT Dry Mouth Lozenges are an over-the-counter (OTC) oral care product designed to provide symptomatic relief for xerostomia (dry mouth). Developed by Chattem, a subsidiary of Sanofi, these sugar-free lozenges utilize xylitol as a primary active ingredient to stimulate natural saliva production. The formulation also includes a blend of three intensive polyol moisturizers and two hydrating polymers that work to soothe and lubricate oral tissues. These lozenges are intended for individuals experiencing dry mouth due to medications, medical conditions, or other factors, and are available in flavors such as Soothing Mint and Honey-Lemon.

Brand names: ACT Dry Mouth Lozenges

Targets

TAS1R3 (Sweet taste receptor T1R3 subunit)TAS1R2 (Taste receptor type 1 member 2)

Beyond the preview

Go deeper on ACT Dry Mouth Lozenges.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT Dry Mouth Lozenges.

Explore the full profile